Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions.

Yokoyama H, Yaguchi T, Suzuki Y, Tokuoka K, Watanabe M, Kitagawa Y, Yamada Y.

Biol Pharm Bull. 2012;35(12):2112-8. Epub 2012 Oct 5.

2.

Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.

Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, Kleiman NS.

J Thromb Haemost. 2007 Mar;5(3):490-6.

3.
4.

Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.

Guthikonda S, Mangalpally K, Vaduganathan M, Patel R, Delao T, Bergeron AL, Dong JF, Lev EI, Kleiman NS.

Thromb Haemost. 2008 Jul;100(1):83-9. doi: 10.1160/TH07-10-0590.

PMID:
18612542
5.
6.

Human pharmacology of naproxen sodium.

Capone ML, Tacconelli S, Sciulli MG, Anzellotti P, Di Francesco L, Merciaro G, Di Gregorio P, Patrignani P.

J Pharmacol Exp Ther. 2007 Aug;322(2):453-60. Epub 2007 May 1.

7.

Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".

Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davì G, Patrono C.

J Am Coll Cardiol. 2009 Feb 24;53(8):667-77. doi: 10.1016/j.jacc.2008.10.047.

8.
9.

Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.

Maenthaisong R, Tacconelli S, Sritara P, Del Boccio P, Di Francesco L, Sacchetta P, Archararit N, Aryurachai K, Patrignani P, Suthisisang C.

Int J Immunopathol Pharmacol. 2013 Apr-Jun;26(2):403-17.

PMID:
23755755
10.

Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.

Pettinella C, Romano M, Stuppia L, Santilli F, Liani R, Davì G.

Thromb Haemost. 2009 Apr;101(4):687-90.

PMID:
19350112
11.

A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.

Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman SA.

J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1509-15.

PMID:
11185674
12.

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.

Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US.

Circulation. 2007 Jun 26;115(25):3156-64. Epub 2007 Jun 11.

13.

Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model.

Awa K, Satoh H, Hori S, Sawada Y.

J Clin Pharm Ther. 2012 Aug;37(4):469-74. doi: 10.1111/j.1365-2710.2011.01313.x. Epub 2011 Nov 28.

PMID:
22122406
14.

Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.

Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, Tomasello SD, Capranzano P, Seecheran N, Darlington A, Tello-Montoliu A, Desai B, Bass TA, Angiolillo DJ.

Circ Cardiovasc Interv. 2011 Apr 1;4(2):180-7. doi: 10.1161/CIRCINTERVENTIONS.110.960187. Epub 2011 Mar 8.

15.

Influence of nonsteroidal anti-inflammatory drugs on the antiplatelet effects of aspirin in rats.

Akagi Y, Nio Y, Shimada S, Aoyama T.

Biol Pharm Bull. 2011;34(2):233-7.

16.

Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects.

Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE.

Clin Pharmacokinet. 2008;47(2):129-37.

PMID:
18193919
17.

Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.

Anzellotti P, Capone ML, Jeyam A, Tacconelli S, Bruno A, Tontodonati P, Di Francesco L, Grossi L, Renda G, Merciaro G, Di Gregorio P, Price TS, Garcia Rodriguez LA, Patrignani P.

Arthritis Rheum. 2011 Mar;63(3):850-9. doi: 10.1002/art.30175.

18.

Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.

Rotondo S, Krauze-Brzósko K, Manarini S, Evangelista V, Cerletti C.

Eur J Pharmacol. 2004 Mar 19;488(1-3):79-83.

PMID:
15044038
19.

Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.

Kobzar G, Mardla V, Samel N.

Platelets. 2011;22(5):338-44. doi: 10.3109/09537104.2010.535931. Epub 2011 May 11.

PMID:
21557683
20.

Dose- and time-dependent antiplatelet effects of aspirin.

Perneby C, Wallén NH, Rooney C, Fitzgerald D, Hjemdahl P.

Thromb Haemost. 2006 Apr;95(4):652-8.

PMID:
16601836

Supplemental Content

Support Center